An object of the present invention is to provide a novel combination of substances showing effects against coronavirus. The present invention provides a therapeutic agent for coronavirus infection comprising a combination of a pyrazine derivative or a salt thereof and another therapeutic agent for coronavirus infection.

An object of the present invention is to provide a novel combination of substances showing effects against coronavirus. The present invention provides a therapeutic agent for coronavirus infection comprising a combination of a pyrazine derivative or a salt thereof and another therapeutic agent for coronavirus infection.

An object of the present invention is to provide a novel combination of substances showing effects against coronavirus. The present invention provides a therapeutic agent for coronavirus infection comprising a combination of a pyrazine derivative or a salt thereof and another therapeutic agent for coronavirus infection.

The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. ##STR00001## X is selected from the group consisting of O and H; R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl, and R.sup.2 is selected from (C.sub.1 to C.sub.10) alkyl, (C.sub.1 to C.sub.10) alkenyl, (C.sub.1 to C.sub.10) alkynyl, (C.sub.3 to C.sub.10) cycloalkyl, and (C.sub.5 to C.sub.10) cycloalkenyl, and NR.sup.3aR.sup.3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.

The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. ##STR00001## X is selected from the group consisting of O and H; R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl, and R.sup.2 is selected from (C.sub.1 to C.sub.10) alkyl, (C.sub.1 to C.sub.10) alkenyl, (C.sub.1 to C.sub.10) alkynyl, (C.sub.3 to C.sub.10) cycloalkyl, and (C.sub.5 to C.sub.10) cycloalkenyl, and NR.sup.3aR.sup.3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.

The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. ##STR00001## X is selected from the group consisting of O and H; R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl, and R.sup.2 is selected from (C.sub.1 to C.sub.10) alkyl, (C.sub.1 to C.sub.10) alkenyl, (C.sub.1 to C.sub.10) alkynyl, (C.sub.3 to C.sub.10) cycloalkyl, and (C.sub.5 to C.sub.10) cycloalkenyl, and NR.sup.3aR.sup.3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.

A method for treating an early-stage microbial infection comprising determining whether a subject exposed to SARS-CoV-2, Monkeypox virus (MPV, MPXV, or hMPXV) or suspected of being exposed to a microbe, or exposed to another infected with or suspected of being infected with a coronavirus and/or Monkeypox virus, if the subject is infected with the coronavirus and/or Monkeypox virus, administering an antimicrobial agent is provided herein.

A method for treating an early-stage microbial infection comprising determining whether a subject exposed to SARS-CoV-2, Monkeypox virus (MPV, MPXV, or hMPXV) or suspected of being exposed to a microbe, or exposed to another infected with or suspected of being infected with a coronavirus and/or Monkeypox virus, if the subject is infected with the coronavirus and/or Monkeypox virus, administering an antimicrobial agent is provided herein.

Provided is a polypeptide containing the amino acid sequence as shown in SEQ ID NO. 1, and the present invention belongs to the field of biomedicine. The polypeptide can inhibit the infection with novel coronavirus 2019-nCoV (SARS-CoV-2) and SARS-like viruses, and can thus provide good candidate drugs for the prevention and treatment of 2019-nCoV and SARS-like viruses which may break out in the future. Further provided is a polypeptide derivative having palmic acid or cholesterol modifications.

Provided is a polypeptide containing the amino acid sequence as shown in SEQ ID NO. 1, and the present invention belongs to the field of biomedicine. The polypeptide can inhibit the infection with novel coronavirus 2019-nCoV (SARS-CoV-2) and SARS-like viruses, and can thus provide good candidate drugs for the prevention and treatment of 2019-nCoV and SARS-like viruses which may break out in the future. Further provided is a polypeptide derivative having palmic acid or cholesterol modifications.